Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo
Open Access
- 20 December 2016
- journal article
- research article
- Published by Springer Nature in Retrovirology
- Vol. 13 (1) , 1-9
Abstract
Despite the durable viral suppression afforded by antiretroviral therapy, HIV-1 eradication will require strategies to target latently infected cells that persist in infected individuals. Protein kinase C (PKC) activation is a promising strategy to reactivate latent proviruses and allow for subsequent recognition and clearance of infected cells by the immune system. Ingenol derivatives are PKC agonists that induce latency reversal but also lead to T cell activation and the release of pro-inflammatory cytokines, which would be undesirable in vivo. In this work, we sought to identify compounds that would suppress pro-inflammatory cytokine production in the context of PKC activation. We performed an in vitro screen to identify compounds that could dampen pro-inflammatory cytokine release associated with T cell activation, using IL-6 as a model cytokine. We then tested the ability of the most promising screening hit, the FDA-approved Janus Kinase (JAK) inhibitor ruxolitinib, to diminish release of multiple cytokines and its effect on latency reversal using cells from HIV-1-positive, aviremic participants. We demonstrate that co-administration of ruxolitinib with ingenol-3,20-dibenzoate significantly reduces pro-inflammatory cytokine release without impairing latency reversal ex vivo. The combination of ingenol compounds and JAK inhibition represents a novel strategy for HIV-1 eradication.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (US) (R21/R33 AI122377-01)
- National Heart, Lung, and Blood Institute (US) (R01 HL126547)
- National Center for Advancing Translational Sciences (US) (1KL2TR001065)
- Doris Duke Charitable Foundation (US) (2016102)
This publication has 37 references indexed in Scilit:
- Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trialThe Lancet HIV, 2014
- Ingenol Mebutate: A Succinct Review of a Succinct TherapyDermatology and Therapy, 2014
- Ruxolitinib and Tofacitinib Are Potent and Selective Inhibitors of HIV-1 Replication and Virus ReactivationIn VitroAntimicrobial Agents and Chemotherapy, 2014
- New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivoNature Medicine, 2014
- HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of VorinostatThe Journal of Infectious Diseases, 2014
- A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral TherapyClinical Infectious Diseases, 2013
- Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradicationAIDS, 2010
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisNew England Journal of Medicine, 2010
- Intensification and Stimulation Therapy for Human Immunodeficiency Virus Type 1 Reservoirs in Infected Persons Receiving Virally Suppressive Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2002
- Early establishment of a pool of latently infected, resting CD4 + T cells during primary HIV-1 infectionProceedings of the National Academy of Sciences, 1998